Key features and details
- Rabbit polyclonal to RANTES
- Suitable for: Sandwich ELISA
- Reacts with: Recombinant fragment
- Isotype: unknown
Product nameAnti-RANTES antibody
See all RANTES primary antibodies
DescriptionRabbit polyclonal to RANTES
Tested applicationsSuitable for: Sandwich ELISAmore details
Species reactivityReacts with: Recombinant fragment
Highly pure (>98%) recombinant hRANTES (human RANTES)
Although some customers have been successful in IHC we no longer batch test in this application.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
FormLyophilized:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferNo preservative, sterile filtered
Concentration information loading...
PurityImmunogen affinity purified
Light chain typeunknown
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9679 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Use at an assay dependent concentration.
FunctionChemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. Binds to CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils.
Tissue specificityT-cell and macrophage specific.
Sequence similaritiesBelongs to the intercrine beta (chemokine CC) family.
modificationsN-terminal processed form RANTES(3-68) is produced by proteolytic cleavage, probably by DPP4, after secretion from peripheral blood leukocytes and cultured sarcoma cells.
The identity of the O-linked saccharides at Ser-27 and Ser-28 are not reported in PubMed:1380064. They are assigned by similarity.
- Information by UniProt
- Beta chemokine RANTES antibody
- Beta chemokine RANTES precursor antibody
- C C motif chemokine 5 antibody
ab9679 has been referenced in 20 publications.
- Fujimoto Y et al. Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Sci 111:209-218 (2020). PubMed: 31724785
- Kochumon S et al. Elevated adipose tissue associated IL-2 expression in obesity correlates with metabolic inflammation and insulin resistance. Sci Rep 10:16364 (2020). PubMed: 33004937
- Zlotkowska A & Andronowska A Variable chemokine expression in porcine trophoblasts and endometrium during the peri-implantation period. Theriogenology 131:16-27 (2019). PubMed: 30928625
- Jin S et al. Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 + T cells in benign prostatic hyperplasia. Prostate 79:909-919 (2019). PubMed: 30958912
- Xiang P et al. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling. Prostate 79:1018-1031 (2019). PubMed: 31018021